Homocysteine and risk of cardiovascular disease among postmenopausal women
- PMID: 10340369
- DOI: 10.1001/jama.281.19.1817
Homocysteine and risk of cardiovascular disease among postmenopausal women
Abstract
Context: Individuals with elevated levels of homocysteine tend to have higher prevalence of cardiovascular disease. However, prospective studies of homocysteine are inconsistent and data among women are limited.
Objective: To determine whether elevated homocysteine levels in healthy postmenopausal women predict risk of developing cardiovascular disease.
Design: Prospective, nested case-control study with a mean 3-year follow-up.
Setting: The Women's Health Study, an ongoing US primary prevention trial initiated in 1993.
Participants: From a total cohort of 28,263 postmenopausal women with no history of cardiovascular disease or cancer at baseline, 122 women who subsequently experienced cardiovascular events were defined as cases, and 244 age- and smoking status-matched women who remained free of disease during follow-up were defined as controls.
Main outcome measures: Incidence of death due to cardiovascular disease, nonfatal myocardial infarction (MI), stroke, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft by baseline homocysteine level.
Results: Of the 122 cases, there were 85 events of MI or stroke and 37 coronary revascularizations. Case subjects had significantly higher baseline homocysteine levels than controls (14.1 vs 12.4 micromol/L; P = .02). Subjects with homocysteine levels in the highest quartile had a 2-fold increase in risk of any cardiovascular event (relative risk [RR], 2.0; 95% confidence interval [CI], 1.1-3.8). This effect was largely due to an excess of cases with high levels of homocysteine; the RR for those with homocysteine levels at or higher than the 95th percentile (20.7 micromol/L) was 2.6 (95% CI, 1.1-5.7). Risk estimates were independent of traditional risk factors and were greatest for the end points of MI and stroke (RR for those with baseline homocysteine levels in the top quartile, 2.2; 95% CI, 1.1-4.6). Self-reported multivitamin supplement use at study entry was associated with significantly reduced levels of homocysteine (P<.001). However, the association between increasing quartile of homocysteine level and risk of MI or stroke remained significant in analyses controlling for baseline multivitamin supplement use (P = .003 for trend), and subgroup analyses limited to women who were (P = .02 for trend) or were not (P = .04 for trend) taking multivitamin supplements.
Conclusions: Among healthy postmenopausal US women, elevated levels of homocysteine moderately increased the risk of future cardiovascular disease. Whether lowering the homocysteine level reduces risk of cardiovascular events requires testing in randomized controlled trials.
Similar articles
-
Homocysteine-lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev. 2013 Jan 31;(1):CD006612. doi: 10.1002/14651858.CD006612.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2015 Jan 15;1:CD006612. doi: 10.1002/14651858.CD006612.pub4. PMID: 23440809 Updated. Review.
-
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study.Arch Intern Med. 2005 Mar 14;165(5):500-8. doi: 10.1001/archinte.165.5.500. Arch Intern Med. 2005. PMID: 15767524
-
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.JAMA. 2004 Feb 4;291(5):565-75. doi: 10.1001/jama.291.5.565. JAMA. 2004. PMID: 14762035 Clinical Trial.
-
Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.JAMA. 2002 Aug 28;288(8):980-7. doi: 10.1001/jama.288.8.980. JAMA. 2002. PMID: 12190368
-
Homocysteine, hypertension and stroke.J Hum Hypertens. 1999 May;13(5):289-93. doi: 10.1038/sj.jhh.1000803. J Hum Hypertens. 1999. PMID: 10376845 Review.
Cited by
-
Homocysteine Is Associated With Future Venous Thromboembolism in 2 Prospective Cohorts of Women.Arterioscler Thromb Vasc Biol. 2021 Jul;41(7):2215-2224. doi: 10.1161/ATVBAHA.121.316397. Epub 2021 May 27. Arterioscler Thromb Vasc Biol. 2021. PMID: 34039021 Free PMC article.
-
Association of Severity and Prognosis With Elevated Homocysteine Levels in Patients With Intracerebral Hemorrhage.Front Neurol. 2020 Oct 19;11:571585. doi: 10.3389/fneur.2020.571585. eCollection 2020. Front Neurol. 2020. PMID: 33193018 Free PMC article.
-
Long-term effects of western diet consumption in male and female mice.Sci Rep. 2020 Sep 7;10(1):14686. doi: 10.1038/s41598-020-71592-9. Sci Rep. 2020. PMID: 32895402 Free PMC article.
-
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.J Am Coll Cardiol. 2020 May 5;75(17):2122-2135. doi: 10.1016/j.jacc.2020.02.059. J Am Coll Cardiol. 2020. PMID: 32354380 Free PMC article. Clinical Trial.
-
Cardiovascular Diseases and Homocysteine, a Short Summary of a Long story.EJIFCC. 2003 Dec 2;14(3):128-130. eCollection 2003 Dec. EJIFCC. 2003. PMID: 30275812 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources